Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 117

1.

P-selectin inhibition therapeutically promotes thrombus resolution and prevents vein wall fibrosis better than enoxaparin and an inhibitor to von Willebrand factor.

Diaz JA, Wrobleski SK, Alvarado CM, Hawley AE, Doornbos NK, Lester PA, Lowe SE, Gabriel JE, Roelofs KJ, Henke PK, Schaub RG, Wakefield TW, Myers DD Jr.

Arterioscler Thromb Vasc Biol. 2015 Apr;35(4):829-37. doi: 10.1161/ATVBAHA.114.304457. Epub 2015 Feb 5.

2.

P-Selectin Inhibition Therapeutically Promotes Thrombus Resolution and Prevents Vein Wall Fibrosis Better than Enoxaparin and an Inhibitor to von Willebrand Factor.

Diaz JA, Wrobleski SK, Pechota AR, Hawley AE, Roelofs KJ, Doornbos NK, Gabriel JE, Reynolds G, Lester P, Londy F, Lowe S, Henke PK, Schaub RG, Wakefield TW, Myers DD.

J Vasc Surg Venous Lymphat Disord. 2014 Jan;2(1):114. doi: 10.1016/j.jvsv.2013.10.032. Epub 2013 Dec 12. No abstract available.

PMID:
26993008
3.

Drug-drug interaction of the anti-TFPI aptamer BAX499 and factor VIII: studies of spatial dynamics of fibrin clot formation in hemophilia A.

Parunov LA, Soshitova NP, Fadeeva OA, Balandina AN, Kopylov KG, Kumskova MA, Gilbert JC, Schaub RG, McGinness KE, Ataullakhanov FI, Panteleev MA.

Thromb Res. 2014 Jan;133(1):112-9. doi: 10.1016/j.thromres.2013.10.036. Epub 2013 Nov 1.

PMID:
24263002
4.

Aptamer BAX 499 mediates inhibition of tissue factor pathway inhibitor via interaction with multiple domains of the protein.

Waters EK, Genga RM, Thomson HA, Kurz JC, Schaub RG, Scheiflinger F, McGinness KE.

J Thromb Haemost. 2013 Jun;11(6):1137-45. doi: 10.1111/jth.12201.

5.

Inhibition of tissue factor pathway inhibitor by the aptamer BAX499 improves clotting of hemophilic blood and plasma.

Gorczyca ME, Nair SC, Jilma B, Priya S, Male C, Reitter S, Knoebl P, Gilbert JC, Schaub RG, Dockal M, McGinness KE, Pabinger I, Srivastava A.

J Thromb Haemost. 2012 Aug;10(8):1581-90. doi: 10.1111/j.1538-7836.2012.04790.x.

6.

ARC15105 is a potent antagonist of von Willebrand factor mediated platelet activation and adhesion.

Siller-Matula JM, Merhi Y, Tanguay JF, Duerschmied D, Wagner DD, McGinness KE, Pendergrast PS, Chung JK, Tian X, Schaub RG, Jilma B.

Arterioscler Thromb Vasc Biol. 2012 Apr;32(4):902-9. doi: 10.1161/ATVBAHA.111.237529. Epub 2012 Jan 26.

PMID:
22282355
7.

Improvement of spatial fibrin formation by the anti-TFPI aptamer BAX499: changing clot size by targeting extrinsic pathway initiation.

Parunov LA, Fadeeva OA, Balandina AN, Soshitova NP, Kopylov KG, Kumskova MA, Gilbert JC, Schaub RG, McGinness KE, Ataullakhanov FI, Panteleev MA.

J Thromb Haemost. 2011 Sep;9(9):1825-34. doi: 10.1111/j.1538-7836.2011.04412.x.

8.

Recent advances in the development of coagulation factors and procoagulants for the treatment of hemophilia.

Schaub RG.

Biochem Pharmacol. 2011 Jul 15;82(2):91-8. doi: 10.1016/j.bcp.2011.03.015. Epub 2011 Mar 29. Review.

PMID:
21453683
9.

Aptamer ARC19499 mediates a procoagulant hemostatic effect by inhibiting tissue factor pathway inhibitor.

Waters EK, Genga RM, Schwartz MC, Nelson JA, Schaub RG, Olson KA, Kurz JC, McGinness KE.

Blood. 2011 May 19;117(20):5514-22. doi: 10.1182/blood-2010-10-311936. Epub 2011 Mar 9.

PMID:
21389323
10.

An anti-von Willebrand factor aptamer reduces platelet adhesion among patients receiving aspirin and clopidogrel in an ex vivo shear-induced arterial thrombosis.

Arzamendi D, Dandachli F, Théorêt JF, Ducrocq G, Chan M, Mourad W, Gilbert JC, Schaub RG, Tanguay JF, Merhi Y.

Clin Appl Thromb Hemost. 2011 Nov-Dec;17(6):E70-8. doi: 10.1177/1076029610384114. Epub 2010 Nov 15.

PMID:
21078615
11.

Inhibition of cell adhesion by anti-P-selectin aptamer: a new potential therapeutic agent for sickle cell disease.

Gutsaeva DR, Parkerson JB, Yerigenahally SD, Kurz JC, Schaub RG, Ikuta T, Head CA.

Blood. 2011 Jan 13;117(2):727-35. doi: 10.1182/blood-2010-05-285718. Epub 2010 Oct 6.

12.

Discovery of 2-[1-(4-chlorophenyl)cyclopropyl]-3-hydroxy-8-(trifluoromethyl)quinoline-4-carboxylic acid (PSI-421), a P-selectin inhibitor with improved pharmacokinetic properties and oral efficacy in models of vascular injury.

Huang A, Moretto A, Janz K, Lowe M, Bedard PW, Tam S, Di L, Clerin V, Sushkova N, Tchernychev B, Tsao DH, Keith JC, Shaw GD, Schaub RG, Wang Q, Kaila N.

J Med Chem. 2010 Aug 26;53(16):6003-17. doi: 10.1021/jm9013696.

PMID:
20718494
13.

The aptamer ARC1779 blocks von Willebrand factor-dependent platelet function in patients with thrombotic thrombocytopenic purpura ex vivo.

Mayr FB, Knöbl P, Jilma B, Siller-Matula JM, Wagner PG, Schaub RG, Gilbert JC, Jilma-Stohlawetz P.

Transfusion. 2010 May;50(5):1079-87. doi: 10.1111/j.1537-2995.2009.02554.x. Epub 2010 Jan 8.

PMID:
20070617
14.

P-selectin/ PSGL-1 inhibitors versus enoxaparin in the resolution of venous thrombosis: a meta-analysis.

Ramacciotti E, Myers DD Jr, Wrobleski SK, Deatrick KB, Londy FJ, Rectenwald JE, Henke PK, Schaub RG, Wakefield TW.

Thromb Res. 2010 Apr;125(4):e138-42. doi: 10.1016/j.thromres.2009.10.022. Epub 2009 Dec 4.

15.

A structural explanation for the antithrombotic activity of ARC1172, a DNA aptamer that binds von Willebrand factor domain A1.

Huang RH, Fremont DH, Diener JL, Schaub RG, Sadler JE.

Structure. 2009 Nov 11;17(11):1476-84. doi: 10.1016/j.str.2009.09.011.

16.

The aptamer ARC1779 is a potent and specific inhibitor of von Willebrand Factor mediated ex vivo platelet function in acute myocardial infarction.

Spiel AO, Mayr FB, Ladani N, Wagner PG, Schaub RG, Gilbert JC, Jilma B.

Platelets. 2009 Aug;20(5):334-40. doi: 10.1080/09537100903085927.

PMID:
19637097
17.

Dose-dependent thrombus resolution due to oral plaminogen activator inhibitor (PAI)-1 inhibition with tiplaxtinin in a rat stenosis model of venous thrombosis.

Baxi S, Crandall DL, Meier TR, Wrobleski S, Hawley A, Farris D, Elokdah H, Sigler R, Schaub RG, Wakefield T, Myers D.

Thromb Haemost. 2008 Apr;99(4):749-58. doi: 10.1160/TH07-11-0669.

PMID:
18392333
18.

Prophylactic P-selectin inhibition with PSI-421 promotes resolution of venous thrombosis without anticoagulation.

Meier TR, Myers DD Jr, Wrobleski SK, Zajkowski PJ, Hawley AE, Bedard PW, Ballard NE, Londy FJ, Kaila N, Vlasuk GP, Schaub RG, Wakefield TW.

Thromb Haemost. 2008 Feb;99(2):343-51. doi: 10.1160/TH07-10-0608.

PMID:
18278184
19.

Aptamers as candidate therapeutics for cardiovascular indications.

Keefe AD, Schaub RG.

Curr Opin Pharmacol. 2008 Apr;8(2):147-52. doi: 10.1016/j.coph.2007.12.005. Epub 2008 Jan 28. Review.

PMID:
18222730
20.

First-in-human evaluation of anti von Willebrand factor therapeutic aptamer ARC1779 in healthy volunteers.

Gilbert JC, DeFeo-Fraulini T, Hutabarat RM, Horvath CJ, Merlino PG, Marsh HN, Healy JM, Boufakhreddine S, Holohan TV, Schaub RG.

Circulation. 2007 Dec 4;116(23):2678-86. Epub 2007 Nov 19.

PMID:
18025536
21.

Characterization of the novel P-selectin inhibitor PSI-697 [2-(4-chlorobenzyl)-3-hydroxy-7,8,9,10-tetrahydrobenzo[h] quinoline-4-carboxylic acid] in vitro and in rodent models of vascular inflammation and thrombosis.

Bedard PW, Clerin V, Sushkova N, Tchernychev B, Antrilli T, Resmini C, Keith JC Jr, Hennan JK, Kaila N, Debernardo S, Janz K, Wang Q, Crandall DL, Schaub RG, Shaw GD, Carter LL.

J Pharmacol Exp Ther. 2008 Feb;324(2):497-506. Epub 2007 Nov 16.

PMID:
18024786
22.

The von Willebrand factor antagonist (GPG-290) prevents coronary thrombosis without prolongation of bleeding time.

Wadanoli M, Sako D, Shaw GD, Schaub RG, Wang Q, Tchernychev B, Xu J, Porter TJ, Huang Q.

Thromb Haemost. 2007 Aug;98(2):397-405.

PMID:
17721623
23.

Serum myeloperoxidase levels are associated with the future risk of coronary artery disease in apparently healthy individuals: the EPIC-Norfolk Prospective Population Study.

Meuwese MC, Stroes ES, Hazen SL, van Miert JN, Kuivenhoven JA, Schaub RG, Wareham NJ, Luben R, Kastelein JJ, Khaw KT, Boekholdt SM.

J Am Coll Cardiol. 2007 Jul 10;50(2):159-65. Epub 2007 Jun 21.

24.

Resolution of venous thrombosis using a novel oral small-molecule inhibitor of P-selectin (PSI-697) without anticoagulation.

Myers DD Jr, Wrobleski SK, Longo C, Bedard PW, Kaila N, Shaw GD, Londy FJ, Rohrer SE, Fex BA, Zajkowski PJ, Meier TR, Hawley AE, Farris DM, Ballard NE, Henke PK, Schaub RG, Wakefield TW.

Thromb Haemost. 2007 Mar;97(3):400-7.

PMID:
17334507
25.

2-(4-Chlorobenzyl)-3-hydroxy-7,8,9,10-tetrahydrobenzo[H]quinoline-4-carboxylic acid (PSI-697): identification of a clinical candidate from the quinoline salicylic acid series of P-selectin antagonists.

Kaila N, Janz K, Huang A, Moretto A, DeBernardo S, Bedard PW, Tam S, Clerin V, Keith JC Jr, Tsao DH, Sushkova N, Shaw GD, Camphausen RT, Schaub RG, Wang Q.

J Med Chem. 2007 Jan 11;50(1):40-64.

PMID:
17201409
26.

Treatment with an oral small molecule inhibitor of P selectin (PSI-697) decreases vein wall injury in a rat stenosis model of venous thrombosis.

Myers DD Jr, Henke PK, Bedard PW, Wrobleski SK, Kaila N, Shaw G, Meier TR, Hawley AE, Schaub RG, Wakefield TW.

J Vasc Surg. 2006 Sep;44(3):625-32.

27.

Effect of von Willebrand factor on the pharmacokinetics of recombinant human platelet glycoprotein Ibalpha-immunoglobulin G1 chimeric proteins.

Wang Q, Shorten D, Xu X, Shaw GD, Schaub RG, Shea C, Brooks J, Sako D, Wiswall E, Xu J, Szklut P, Patel VS.

Pharm Res. 2006 Aug;23(8):1743-9.

PMID:
16850270
28.

Pharmacologic inhibition of platelet vWF-GPIb alpha interaction prevents coronary artery thrombosis.

Hennan JK, Swillo RE, Morgan GA, Leik CE, Brooks JM, Shaw GD, Schaub RG, Crandall DL, Vlasuk GP.

Thromb Haemost. 2006 Mar;95(3):469-75.

PMID:
16525575
29.

Rotigaptide (ZP123) prevents spontaneous ventricular arrhythmias and reduces infarct size during myocardial ischemia/reperfusion injury in open-chest dogs.

Hennan JK, Swillo RE, Morgan GA, Keith JC Jr, Schaub RG, Smith RP, Feldman HS, Haugan K, Kantrowitz J, Wang PJ, Abu-Qare A, Butera J, Larsen BD, Crandall DL.

J Pharmacol Exp Ther. 2006 Apr;317(1):236-43. Epub 2005 Dec 12.

PMID:
16344331
30.

Decreased venous thrombosis with an oral inhibitor of P selectin.

Myers DD Jr, Rectenwald JE, Bedard PW, Kaila N, Shaw GD, Schaub RG, Farris DM, Hawley AE, Wrobleski SK, Henke PK, Wakefield TW.

J Vasc Surg. 2005 Aug;42(2):329-36.

31.

Prevention of in-stent restenosis via reduction of thrombo-inflammatory reactions with recombinant P-selectin glycoprotein ligand-1.

Tanguay JF, Geoffroy P, Sirois MG, Libersan D, Kumar A, Schaub RG, Merhi Y.

Thromb Haemost. 2004 Jun;91(6):1186-93.

PMID:
15175806
32.

P-selectin and leukocyte microparticles are associated with venous thrombogenesis.

Myers DD, Hawley AE, Farris DM, Wrobleski SK, Thanaporn P, Schaub RG, Wagner DD, Kumar A, Wakefield TW.

J Vasc Surg. 2003 Nov;38(5):1075-89. Erratum in: J Vasc Surg. 2004 Jan;39(1):188.

33.

Reduced bleeding events with subcutaneous administration of recombinant human factor IX in immune-tolerant hemophilia B dogs.

Russell KE, Olsen EH, Raymer RA, Merricks EP, Bellinger DA, Read MS, Rup BJ, Keith JC Jr, McCarthy KP, Schaub RG, Nichols TC.

Blood. 2003 Dec 15;102(13):4393-8. Epub 2003 Aug 21.

PMID:
12933577
34.

Interaction of P-selectin and PSGL-1 generates microparticles that correct hemostasis in a mouse model of hemophilia A.

Hrachovinová I, Cambien B, Hafezi-Moghadam A, Kappelmayer J, Camphausen RT, Widom A, Xia L, Kazazian HH Jr, Schaub RG, McEver RP, Wagner DD.

Nat Med. 2003 Aug;9(8):1020-5. Epub 2003 Jul 13.

PMID:
12858167
35.

Comparative response of plasma VWF in dogs to up-regulation of VWF mRNA by interleukin-11 versus Weibel-Palade body release by desmopressin (DDAVP).

Olsen EH, McCain AS, Merricks EP, Fischer TH, Dillon IM, Raymer RA, Bellinger DA, Fahs SA, Montgomery RR, Keith JC Jr, Schaub RG, Nichols TC.

Blood. 2003 Jul 15;102(2):436-41. Epub 2003 Mar 20.

PMID:
12649145
36.

P-selectin inhibition enhances thrombus resolution and decreases vein wall fibrosis in a rat model.

Myers DD Jr, Henke PK, Wrobleski SK, Hawley AE, Farris DM, Chapman AM, Knipp BS, Thanaporn P, Schaub RG, Greenfield LJ, Wakefield TW.

J Vasc Surg. 2002 Nov;36(5):928-38.

PMID:
12422103
37.

Recombinant soluble P-selectin glycoprotein ligand-Ig (rPSGL-Ig) attenuates infarct size and myeloperoxidase activity in a canine model of ischemia-reperfusion.

Wang K, Zhou X, Zhou Z, Tarakji K, Qin JX, Sitges M, Shiota T, Forudi F, Schaub RG, Kumar A, Penn MS, Topol EJ, Lincoff AM.

Thromb Haemost. 2002 Jul;88(1):149-54.

PMID:
12152656
38.

Preclinical pharmacology of albumin-free B-domain deleted recombinant factor VIII.

Brinkhous K, Sandberg H, Widlund L, Read M, Nichols T, Sigman J, Oswaldsson U, Schaub RG, Mikaelsson M.

Semin Thromb Hemost. 2002 Jun;28(3):269-72. Review.

PMID:
12098087
39.

Pharmacokinetics of recombinant factor IX after intravenous and subcutaneous administration in dogs and cynomolgus monkeys.

McCarthy K, Stewart P, Sigman J, Read M, Keith JC Jr, Brinkhous KM, Nichols TC, Schaub RG.

Thromb Haemost. 2002 May;87(5):824-30.

PMID:
12038784
40.

Intratracheal administration of recombinant human factor IX (BeneFix) achieves therapeutic levels in hemophilia B dogs.

Russell KE, Read MS, Bellinger DA, Leitermann K, Rup BJ, McCarthy KP, Keith JC Jr, Khor SP, Schaub RG, Nichols TC.

Thromb Haemost. 2001 Mar;85(3):445-9.

PMID:
11307812
41.
42.
43.

Recombinant soluble p-selectin glycoprotein ligand-1-Ig reduces restenosis through inhibition of platelet-neutrophil adhesion after double angioplasty in swine.

Bienvenu JG, Tanguay JF, Théorêt JF, Kumar A, Schaub RG, Merhi Y.

Circulation. 2001 Feb 27;103(8):1128-34.

PMID:
11222477
44.

Interleukin 11 significantly increases plasma von Willebrand factor and factor VIII in wild type and von Willebrand disease mouse models.

Denis CV, Kwack K, Saffaripour S, Maganti S, André P, Schaub RG, Wagner DD.

Blood. 2001 Jan 15;97(2):465-72.

PMID:
11154224
45.

P-Selectin-dependent inhibition of thrombosis during venous stasis.

Eppihimer MJ, Schaub RG.

Arterioscler Thromb Vasc Biol. 2000 Nov;20(11):2483-8.

PMID:
11073856
46.

Vaccines with interleukin-12-transduced acute myeloid leukemia cells elicit very potent therapeutic and long-lasting protective immunity.

Dunussi-Joannopoulos K, Runyon K, Erickson J, Schaub RG, Hawley RG, Leonard JP.

Blood. 1999 Dec 15;94(12):4263-73.

PMID:
10590071
47.

Recombinant soluble form of PSGL-1 accelerates thrombolysis and prevents reocclusion in a porcine model.

Kumar A, Villani MP, Patel UK, Keith JC Jr, Schaub RG.

Circulation. 1999 Mar 16;99(10):1363-9.

PMID:
10077522
48.

Optimal scheduling of interleukin 12 and chemotherapy in the murine MB-49 bladder carcinoma and B16 melanoma.

Teicher BA, Ara G, Buxton D, Leonard J, Schaub RG.

Clin Cancer Res. 1997 Sep;3(9):1661-7.

49.

Optimal scheduling of interleukin-12 and fractionated radiation therapy in the murine Lewis lung carcinoma.

Teicher BA, Ara G, Buxton D, Leonard J, Schaub RG.

Radiat Oncol Investig. 1998;6(2):71-80.

PMID:
9572683
50.

Immunoregulation by interleukin-12 in MB49.1 tumor-bearing mice: cellular and cytokine-mediated effector mechanisms.

Hunter SE, Waldburger KE, Thibodeaux DK, Schaub RG, Goldman SJ, Leonard JP.

Eur J Immunol. 1997 Dec;27(12):3438-46.

PMID:
9464833

Supplemental Content

Loading ...
Support Center